Lee and AstraZeneca: India's next David and Goliath compulsory license fight?
This article was originally published in Scrip
A 40% chance for success and mere "publicity stunt" are some of the sharp early reactions to the surprise compulsory license (CL) application for AstraZeneca's saxagliptin by the Hyderabad-based Lee Pharma, though the less know firm appears confident that its arguments hold water.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?